Zenas BioPharma (NASDAQ:ZBIO) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Zenas BioPharma (NASDAQ:ZBIO) from a hold rating to a sell rating in a report released on Saturday morning.

A number of other equities research analysts have also commented on the stock. Evercore ISI initiated coverage on shares of Zenas BioPharma in a report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price objective on the stock. Morgan Stanley lowered shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $37.00 to $19.00 in a report on Monday, January 5th. Wedbush restated an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a research report on Monday, December 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Finally, Citigroup raised their target price on shares of Zenas BioPharma from $27.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $43.14.

Zenas BioPharma Stock Down 2.0%

Shares of ZBIO opened at $16.08 on Friday. The company has a market capitalization of $863.17 million, a P/E ratio of -2.27 and a beta of -1.45. Zenas BioPharma has a one year low of $5.83 and a one year high of $44.60. The business’s 50 day simple moving average is $34.94 and its 200-day simple moving average is $24.11. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

Insider Buying and Selling at Zenas BioPharma

In related news, CEO Leon O. Moulder, Jr. purchased 50,000 shares of Zenas BioPharma stock in a transaction dated Wednesday, January 7th. The stock was bought at an average price of $16.38 per share, for a total transaction of $819,000.00. Following the completion of the acquisition, the chief executive officer directly owned 316,155 shares of the company’s stock, valued at $5,178,618.90. This represents a 18.79% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have purchased a total of 100,000 shares of company stock valued at $1,639,000 in the last ninety days. 16.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zenas BioPharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Federated Hermes Inc. raised its stake in shares of Zenas BioPharma by 60.8% in the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock valued at $18,041,000 after purchasing an additional 703,838 shares during the period. Vanguard Group Inc. raised its position in Zenas BioPharma by 17.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock valued at $25,813,000 after buying an additional 170,546 shares during the last quarter. Invesco Ltd. bought a new stake in Zenas BioPharma in the 3rd quarter valued at approximately $3,237,000. Millennium Management LLC acquired a new position in Zenas BioPharma during the 3rd quarter worth approximately $1,595,000. Finally, Geode Capital Management LLC grew its stake in shares of Zenas BioPharma by 4.6% during the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after acquiring an additional 16,461 shares in the last quarter.

Zenas BioPharma News Roundup

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: CEO insider purchases — Leon Moulder Jr. bought a total of ~100,000 shares across Jan. 7–9 (50k @ $16.38, 30k @ $16.30, 20k @ $16.55), spending roughly $1.63M and raising his direct stake to ~366,155 shares (~$6.06M value). Large, repeated CEO buys often signal management confidence and can attract buying interest. Zenas Biopharma (ZBIO) CEO Moulder buys $1.63m in stock
• Positive Sentiment: Analyst backdrop is constructive — brokerages’ consensus rating sits at “Moderate Buy” with several buy/outperform opinions and elevated average price targets, which can support demand if sentiment persists. Zenas BioPharma Given Consensus Recommendation of “Moderate Buy”
• Neutral Sentiment: SEC filings confirm timing and price — multiple Form 4 disclosures document the CEO’s transactions, providing transparency on cost basis and validating the insider activity for investors doing due diligence. SEC filing confirming insider purchases
• Neutral Sentiment: Mixed analyst and price‑target dispersion — while many firms are bullish, some recent revisions (e.g., Morgan Stanley trimming its target) create varied upside expectations that can mute a clear consensus move. MarketBeat ZBIO analyst summary
• Negative Sentiment: Litigation/investigation headline risk — Pomerantz LLP issued an investor alert investigating Zenas, which can trigger short‑term volatility, legal costs, and investor caution until the scope and findings are clarified. Pomerantz investigates Zenas BioPharma

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.